Class information for:
Level 1: FLUVASTATIN//PLEIOTROPIC EFFECTS//HMG COA REDUCTASE INHIBITOR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3781 1833 43.6 89%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
408 16067 STATINS//EZETIMIBE//SIMVASTATIN

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FLUVASTATIN Author keyword 14 18% 4% 71
2 PLEIOTROPIC EFFECTS Author keyword 10 20% 3% 46
3 HMG COA REDUCTASE INHIBITOR Author keyword 10 14% 3% 62
4 HMG COA REDUCTASE INHIBITORS Author keyword 9 12% 4% 69
5 STATIN WITHDRAWAL Author keyword 6 80% 0% 4
6 PLEIOTROPIC Author keyword 4 25% 1% 14
7 CERIVASTATIN Author keyword 3 17% 1% 19
8 HMG COA REDUCTASE INHIBITION Author keyword 3 32% 0% 8
9 NCX 6560 Author keyword 3 60% 0% 3
10 3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS Author keyword 2 17% 1% 13

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 FLUVASTATIN 14 18% 4% 71 Search FLUVASTATIN Search FLUVASTATIN
2 PLEIOTROPIC EFFECTS 10 20% 3% 46 Search PLEIOTROPIC+EFFECTS Search PLEIOTROPIC+EFFECTS
3 HMG COA REDUCTASE INHIBITOR 10 14% 3% 62 Search HMG+COA+REDUCTASE+INHIBITOR Search HMG+COA+REDUCTASE+INHIBITOR
4 HMG COA REDUCTASE INHIBITORS 9 12% 4% 69 Search HMG+COA+REDUCTASE+INHIBITORS Search HMG+COA+REDUCTASE+INHIBITORS
5 STATIN WITHDRAWAL 6 80% 0% 4 Search STATIN+WITHDRAWAL Search STATIN+WITHDRAWAL
6 PLEIOTROPIC 4 25% 1% 14 Search PLEIOTROPIC Search PLEIOTROPIC
7 CERIVASTATIN 3 17% 1% 19 Search CERIVASTATIN Search CERIVASTATIN
8 HMG COA REDUCTASE INHIBITION 3 32% 0% 8 Search HMG+COA+REDUCTASE+INHIBITION Search HMG+COA+REDUCTASE+INHIBITION
9 NCX 6560 3 60% 0% 3 Search NCX+6560 Search NCX+6560
10 3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS 2 17% 1% 13 Search 3+HYDROXY+3+METHYLGLUTARYL+COENZYME+A+REDUCTASE+INHIBITORS Search 3+HYDROXY+3+METHYLGLUTARYL+COENZYME+A+REDUCTASE+INHIBITORS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 COA REDUCTASE INHIBITORS 53 14% 19% 346
2 COA REDUCTASE INHIBITOR 24 17% 7% 129
3 NORMOCHOLESTEROLEMIC RATS 18 89% 0% 8
4 A REDUCTASE INHIBITOR 14 31% 2% 37
5 LOWER MORTALITY 12 59% 1% 13
6 REDUCTASE INHIBITORS 10 10% 5% 92
7 HYPERCHOLESTEROLEMIC PATIENTS 9 11% 4% 72
8 CHOLESTEROL REDUCTION 6 19% 2% 31
9 SODIUM XU62 320 6 100% 0% 4
10 RHO GTPASE 5 15% 2% 33

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives 2010 207 121 41%
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials 2012 71 133 32%
Pleiotropic effects of statins 2005 706 156 28%
Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering 2014 14 106 39%
Anticoagulant effects of statins and their clinical implications 2014 13 92 40%
Antihypertensive Effects of Statins: A Meta-Analysis of Prospective Controlled Studies 2013 22 48 46%
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results 2008 217 92 25%
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 2001 857 116 34%
Rho GTPases, statins, and nitric oxide 2005 255 28 43%
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy 2008 80 94 53%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 AFFILIATED PUAI HOSP 2 67% 0.1% 2
2 MOL CARDIOVASC PHARMACOL 2 67% 0.1% 2
3 VASC MED ATHEROSCLEROSIS UNIT 2 15% 0.7% 12
4 BRITISH HEART FDNCARDIOVASC MED UNIT 1 50% 0.1% 2
5 EMI 99 12 1 100% 0.1% 2
6 EXCELLENCE NOREG SAS 1 100% 0.1% 2
7 J ROBERT CADE FDN 1 100% 0.1% 2
8 MEDUNIDADE ID CARDIOVASC PORTO 1 40% 0.1% 2
9 HSCSP 1 18% 0.3% 5
10 MED CARDIOL 3 1 27% 0.2% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000231844 P DIS TB INTERNAL MED//3 HYDROXY 3 METHYLGLUTARYL CO ENZYME A REDUCTASE INHIBITOR//INTER PROGRAM IMMUNOL
2 0.0000199081 ABNORMAL BLOOD LIPIDS//BEYIN CERRAHI SERV//BRAIN INJURY GRP BIOMED
3 0.0000146238 NK 104//PITAVASTATIN//CAS 147526 32 7
4 0.0000128731 STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN
5 0.0000102373 LOVASTATIN//BB BIOCYT//PEDIAT PNEUMONOL ALLERG DIS HEMATOL
6 0.0000068642 PERIPROCEDURAL MYOCARDIAL INFARCTION//PERIPROCEDURAL MYOCARDIAL INJURY//PERIOPERATIVE MYOCARDIAL INFARCTION
7 0.0000064938 STATIN MYOPATHY//STATIN INTOLERANCE//MYALGIA
8 0.0000062430 PATOL VASC NEFROL EXPT//VASC RENAL PATHOL//MED ALFREDO LANARI
9 0.0000059483 PRAVASTATIN//HMG COA REDUCTASE INHIBITOR//COMPACTIN
10 0.0000057856 RECEPTOR C K//PLATELET THROMBOXANE FORMATION//REFLECTION CONTRAST MICROSCOPY